FCGR2B抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human placenta tissue, Primary antibody: P08322(FCGR2B Antibody) at dilution 1/850, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08322(FCGR2B Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P08322(FCGR2B Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

Fc gamma receptor IIB (FCGR2B) is an inhibitory immune receptor belonging to the immunoglobulin superfamily, primarily expressed on B cells and myeloid cells. It plays a critical role in modulating immune responses by dampening activation signals upon binding to immune complexes via its intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM). This negative regulation helps maintain immune tolerance and prevent hyperactivation, making FCGR2B a key checkpoint in autoimmune diseases, infections, and cancer.

FCGR2B-targeting antibodies have gained attention for therapeutic and research applications. In autoimmune disorders like systemic lupus erythematosus (SLE), enhancing FCGR2B signaling could suppress pathogenic antibody production. Conversely, in cancer immunotherapy, blocking FCGR2B may counteract its inhibitory effects on effector cells (e.g., macrophages, NK cells), potentially enhancing antitumor activity. However, developing selective antibodies is challenging due to high homology with activating Fc receptors (e.g., FCGR2A).

Genetic polymorphisms in FCGR2B are linked to disease susceptibility, particularly in SLE and malaria. For example, a T→I232 mutation disrupts its function, correlating with autoimmune risk. Research tools like anti-FCGR2B monoclonal antibodies (e.g., clone AT10) are widely used to study receptor expression, signaling crosstalk, and immune cell regulation. Ongoing efforts focus on engineering bispecific antibodies or fusion proteins to fine-tune FCGR2B activity, balancing efficacy and safety in clinical applications.